



0300

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: **NIELSEN=3B**

In re Application of:	)	Art Unit:
NIELSEN, Soeren	)	
	)	Examiner:
	)	
Appln. No.: 09/845,717	)	Washington, D.C.
	)	
Filed: May 02, 2001	)	November 2, 2001
	)	
For: METHODS FOR TREATMENT	)	
OF DISEASES ASSOCIATED	)	
WITH INFLAMMATION UNDER	)	
NON-ISHEMIC CONDITIONS	)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents,

In re of:

publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached.


[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:



Iver P. Cooper  
Reg. No. 28, 005

IPC:tw

624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
F:\nielen3bidstransmittaltopto.doc

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of

1

NOV 02 2001

**Complete if Known**

Application Number	09/845,717
Filing Date	May 02, 2001
First Named Inventor	Soeren Nielsen
Group Art Unit	
Examiner Name	
Attorney Docket Number	NIELSEN=3B

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AA	FRANKLIN, H. et al. Erythropoietin: A Model System For Studying Oxygen-Dependent Gene Regulation, The Journal of Experimental Biology 201, 1197-1201 (24 March 1998)	
	AB	ANNA CATANIA et al. , The Neuropeptide $\alpha$ -MSH Has Specific Receptors On Neutrophils and Reduces Chemotaxis In Vitro Peptides Vol. 17 No. 4PP. 675-679, 1996	
	AC	JOACHIM FANDREY, et al. Cobalt Chloride and Desferrioxamine Antagonize the Inhibition of Erythropoietin Production by Reactive Oxygen Species Kidney International, Vol. 51 (1997) PP. 492-496	
	AD	KWON, TAE-HWAN, et al., Reduced Abundance of Aquaporins in Rats With Bilateral Ischemia-Induced Acute Renal Failure: Prevention By $\alpha$ -MSH, Am.J.Physiol, 277:F413-F427, 1999	
	AE	JAMES M. LIPTON AND ANNA CATANIA, Anti-Inflammatory Actions Of The Neuroimmunomodulator $\alpha$ -MSH, Immunology Today, 18:(3)=140 -145 March (1997)	
	AF	NILUM RAJORA, et al, $\alpha$ -MSH Modulates Local and Circulating Tumor Necrosis Factory- $\alpha$ in Experimental Brain Inflammation, Journal of Neuroscience, March 15, 1997 17(6):2181-2186	
	AG	NILUM RAJORA, et al. $\alpha$ -MSH Modulates Experimental Inflammatory Bowel Disease, Peptides, Vol. 3, pp. 381-385, 1997	
	AH	PETER J. RATCLIFFE, et al., Oxygen Regulated Gene Expression: Erythropoietin as a Model System, Kidney International, Vol. 51 (1997), pp. 514-526	
	AI	YASUTAKA SADAMOT, et al. Erythropoietin Prevents Place Navigation Disability and Cortical infarction in Rats with Permanent Occlusion of the Middle Cerebral Artery, Biochemical and Biophysical Research Communications 253, 26-32 (1998)	
	AJ	MASAHIRO SAKANAKA, et al. IN Vivo Evidence That Erythropoietin Protects Neurons From Ischemic Damage, Proc. Natl. Acad. Sci. USA Vol. 95, pp. 4635-4640, April 1998	
	AK	FRANCESCO SQUADRITO, et al. Adrenocorticotropin Reverses Vascular Dysfunction and Protects Against Splanchnic Artery Occlusion Shock, British Journal of Pharmacology (1999), 128, 816-822	
	AL	FRANCESCO SQUADRITO, et al., Recombinant Human Erythropoietin Inhibits iNOS Activity and Reverts Vascular Dysfunction in Splanchnic Artery Occlusion Shock, British Journal of Pharmacology (1999), 127, 482-488	
	AM	ROBERT A. STAR, et al., Evidence of Autocrine Modulation of Macrophage Nitric oxide Synthase by $\alpha$ -Melanocyte-Stimulation, Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 8016-8020, August 1995	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.